Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.68 |
| ▸ | FAAH | O00519 | 5/20 | 0.62 |
| ▸ | CES1 | P23141 | 5/20 | 0.54 |
| ▸ | CES2 | O00748 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5379286 | 1.00 | CA2 (0.68) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL10336189 | 1.00 | CA2 (0.68) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL8778833 | 1.00 | CA2 (0.68) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL8778769 | 1.00 | CA2 (0.68) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL395321 | 1.00 | CA2 (0.68) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL8778750 | 1.00 | CA2 (0.68) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL11058951 | 1.00 | CA2 (0.68) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL393510 | 1.00 | CA2 (0.68) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL350042 | 1.00 | CA2 (0.68) | CA2FAAHCES1CES2TSHR | |
| SCHEMBL8778763 | 1.00 | CA2 (0.68) | CA2FAAHCES1CES2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105623384-A | Ink carriers containing surface modified nanoparticles, phase change inks including same, and methods for making same | XEROX CORP | 2016-06-01 | — | — | CN | disclosed |
| US-7294369-B2 | Polymerisable cinnamates with lateral substitution | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2007-11-13 | — | — | US | disclosed |
| EP-1524308-B1 | Polymerisable Cinnamates with lateral substitution | MERCK PATENT GMBH (DE) | 2006-07-26 | — | — | EP | disclosed |
| US-20050227021-A1 | Polymerisable cinnamates with lateral substitution | MERCK PATENT GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| EP-1524308-A1 | Polymerisable Cinnamates with lateral substitution | MERCK PATENT GmbH (DE) | 2005-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227021-A1 | Polymerisable cinnamates with lateral substitution | VIM, TYR, LAGE3 | CA2 2174/4885FAAH 2514/4885CES1 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.